ReviewEuropean cytokine network2026
Targeting the cytokine-epigenetic axis: a new paradigm and prospects for disease treatment.
Review in European cytokine network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Jiuwei Xiaozhi Decoction Alleviates High-Fat Diet-Induced MASLD by Suppressing Hepatic SREBP2-Driven Cholesterogenesis and Restoring PPARα-Mediated Fatty Acid Oxidation.Chemical biology & drug design · 2026Article
- Pomegranate Peel Polyphenol Extract Ameliorates Hyperuricemia by Inhibiting Uric Acid Synthesis and Reabsorption.Chemical biology & drug design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cytokines, as key signaling molecules, are involved in the regulation of physiological and pathological processes such as inflammation, immunity, and cell growth. Epigenetic mechanisms, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs, enable precise control of gene expression without changing the DNA sequence. Recent studies have revealed that cytokines interact with epigenetic regulation to form a dynamic and complex "cytokine-epigenetic axis". Through metabolic reprogramming and regulation of epigenetic enzyme activity, this axis affects gene expression patterns at both transcriptional and post-transcriptional levels, thereby contributing to the initiation and progression of various diseases, including autoimmune diseases, neurodegenerative diseases, neuropsychiatric disorders, metabolic diseases, and cancer. Targeting this regulatory axis by combining interventions on upstream cytokine signaling and downstream epigenetic enzymes represents a new precision therapeutic strategy for overcoming resistance to monotherapy and achieving disease-modifying treatment. This review describes how cytokines regulate epigenetic modification substrates through metabolic reprogramming and directly regulate epigenetic enzyme activity via JAK-STAT, NF-κB, and TGF-β/Smad pathways; how this axis drives disease chronicity and therapy resistance across autoimmune, neurodegenerative, metabolic, and neoplastic diseases by establishing long-lasting functional reprogramming; and emerging strategies targeting this axis through combined interventions, precision medicine, and disease memory reprogramming.
Indexed as
Identifiers
42421500What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.